

ASX Announcement

27 February 2025

ReNerve enters partnership for NervAlign® Nerve Cuff in Mexico

Highlights:

- ReNerve has entered a partnership with Imbiomex to progress the NervAlign® Nerve Cuff through regulatory approval and thereafter to commence distribution of the product in Mexico.
- Imbiomex is a Mexican medical device distribution company specialising in the sales and marketing of imported innovations in the biomaterials and surgical markets.
- The Global Nerve Repair Biomaterials Market was valued at USD\$1.96 billion in 2024 and is projected to grow at a CAGR of 17.8% to USD\$6.19 billion¹ by 2031.
- The Mexican market for nerve repair biomaterials has been valued at USD\$74M¹.

ReNerve Limited (ASX:RNV) (“ReNerve” or “the Company”) is pleased to announce that it has signed an exclusive distribution partnership agreement (“the Agreement”) with Imbiomex to progress the NervAlign® Nerve Cuff in Mexico. The two companies have now started the regulatory application process to achieve market approval for the product, following which Imbiomex will market and sell the product in Mexico.

The market for nerve repair biomaterials in Mexico is estimated to be worth around USD\$74M per annum and growing at 17%. With help from Imbiomex, Mexico provides a good opportunity for ReNerve to expand outside the US market and into Latin America.

Commenting on the new partnership, ReNerve CEO, Dr Julian chick, stated: *“We are delighted to be partnering with the Imbiomex team to establish a market presence in Mexico, as part of our broader global expansion strategy. We are especially excited to work with Imbiomex for the Mexican market, given their strong local positioning, as well as their in-depth understanding of the biomaterials and surgical markets, including the peripheral nerve repair market.”*

Imbiomex is a Mexican medical device distribution company that is focused on the sales and marketing of biologics, representing some of the world’s leading tissue companies. Imbiomex has been working in the Mexican biomaterials market for ten years, including importing, warehousing and distributing, as well as working with all types of tissue.

The NervAlign® Nerve Cuff is designed for the protection of repaired nerves and the regeneration of nerves during the healing process. The product is unique as it protects the nerve during the healing process, but is naturally absorbed within 6 months, leaving just regenerated repaired tissue.

¹ Global Nerve Repair Biomaterials Market Research Report (2020 – 2031)



This announcement has been approved for release by the Company's Board of Directors.

- ENDS -

For further information and enquiries, please contact:

Dr Julian Chick

CEO & Managing Director

ReNerve Ltd

+61 (03) 9482 3940

info@renerve.com.au

Jane Morgan

Investor & Media Relations

Jane Morgan Management

+61 (0) 405 555 618

info@janemorganmanagement.com.au

About ReNerve Limited

ReNerve Limited (ASX:RNV) is a medical device company specialising in advanced nerve repair and regeneration solutions. The Company is focused on commercialising cutting-edge medical devices and tissue-engineering products that seek to address significant unmet needs for patients with peripheral nerve damage – a critical gap in healthcare. ReNerve aims to improve patient outcomes through scientifically backed products that have been developed to enhance the human body's natural healing process, while commercialising cutting-edge, scalable products for the healthcare market. ReNerve wishes to acknowledge AusIndustry's Accelerating Commercialisation program for its support through many of the activities required to commercialise the NervAlign® Nerve Cuff.